Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets.
In light of the recently announced agreement to be acquired by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results. The earnings press release will be made available publicly on the Investor Relations page of its website at https://ir.horizontherapeutics.com.
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005183/en/
Contacts
Investor Relations:
Tina Ventura
Senior Vice President, Chief Investor Relations Officer
Investor-relations@horizontherapeutics.com
U.S. Media:
Geoff Curtis
Executive Vice President, Corporate Affairs & Chief Communication Officer
media@horizontherapeutics.com
Ireland Media:
Gordon MRM
Ray Gordon
ray@gordonmrm.ie
